CN Stock MarketDetailed Quotes

688180 Shanghai Junshi Biosciences Co., Ltd.

Watchlist

25.68
-0.60-2.28%

Trading Jan 8 10:40 CST

25.31BMarket Cap-14.03P/E (TTM)

Shanghai Junshi Biosciences Co., Ltd. Stock Forum

Moomoo AI

Mar 5, 2024 16:54

The company's weak revenue trend, unprofitability, and rapid decline in share price reflect poor fundamentals. Last year's performance indicates unresolved challenges, worse than the annualized loss of 9% over the last half decade.

Further Weakness as Shanghai Junshi Biosciences (HKG:1877) Drops 3.2% This Week, Taking Three-year Losses to 83%

Spinee

Jan 17, 2024 02:21

HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off

$Hang Seng Index (800000.HK)$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN (09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B (02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH (01873.HK)$ ...

Moomoo AI

Jan 8, 2024 19:54

Despite Shanghai Junshi Biosciences' weak revenue growth, its P/S ratio aligns with industry peers, indicating investors may be overlooking limited growth expectations and paying a premium. However, this could risk investments as the weak revenue outlook may eventually impact share prices.

Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Price Is Out Of Tune With Revenues

Moomoo AI

Oct 27, 2023 19:26

Shanghai Junshi Biosciences carries rising debt yet has surplus liquid assets, offsetting risk. Despite having net cash, being a loss-maker might impact its financial health. Be cautious of investing until positive cash flow is seen.

Is Shanghai Junshi Biosciences (HKG:1877) Weighed On By Its Debt Load?

ETFWorldSavior

Jun 7, 2023 21:42

Columns Anxin International - Pharmaceutical Industry Biweekly Report: The results of Chinese medicine decoction pieces combined selection landing, 2023ASCO abstract released

Key points:
1. Hang Seng Index fell 2.57% in the first two weeks (2023/05/22 to 2023/06/02), with all 12 Hang Seng industries falling. Among them, the Hang Seng healthcare sector fell 1.51%, outperforming the Hang Seng Index by 1.06 percentage points, ranking third among the 12 Hang Seng industries
2. On May 22, the results of the f...